HC Wainwright initiated coverage of Lyell Immunopharma IncLYEL with a Buy rating and a price target of $12 per share.
Lyell leverages two ex vivo epigenetic reprogramming technologies, Gen-R and Epi-R, which are designed to generate T-cell populations that are more effective and resilient.
The analyst believes the technologies position Lyell as a solid tumor cell therapy leader.
LYL845 is a tumor-infiltrating lymphocyte (TIL) therapy designed to incorporate the Epi-R technology.
HC Wainwright says LYL845 design can potentially help overcome challenges associated with competing TIL products, including limited efficacy due to poor enrichment of tumor-reactive T cells, poor quality and growth potential of expanded T cells, and failure to maintain polyclonality of TILs during production.
Earlier this month, the FDA cleared the Investigational New Drug application to initiate a Phase 1 trial for LYL845.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
